Viromed Medical AG Successfully Completes Capital Increase

Viromed Medical AG has announced the successful completion of its capital increase. The company placed 450,000 new registered no-par value shares at EUR 4.50 each, generating gross proceeds of approximately EUR 2 million. These funds are earmarked for financing the working capital of the company.

Pending the new capital's registration, share capital is set to rise from EUR 21,250,000 to EUR 21,700,000. The increase was made possible by utilizing the Authorized Capital 2025 and excluding shareholders' subscription rights.

Viromed focuses on developing and distributing medical products, with a notable emphasis on innovative cold plasma technology. Since its stock exchange listing in October 2022, the company has been expanding its operations in the DACH region and pursuing further advancements in medical technology.